Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCTIC: Durvalumab +/- Tremelimumab in Advanced NSCLC
NCT02352948Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2015
- Primary completion
- Feb 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 26
01
Overview
A Phase 3 trial of durvalumab, tremelimumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jan 2015; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02352948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352948.